RxDoctor Payments DataLook up a doctor →

Ryan Klein, MD

Internal Medicine · Newport Beach, CANPI 1184620866

Payments from drug & device makers

$5,005,752in general payments, 2019–2025

Across 2,208 payments — averaging $2267.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2.2M
  • Boehringer Ingelheim$492K
  • GSK$326K
  • United Therapeutics Corporation$279K
  • Insmed, Inc.$245K
  • Astrazeneca UK Limited$226K
  • plus $1.2M from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca199$2,209,848
Boehringer Ingelheim147$492,458
GSK249$326,393
United Therapeutics Corporation72$278,543
Insmed, Inc.262$244,629
Astrazeneca UK Limited17$226,010
Sanofi US Services Inc.30$197,763
Cipla USA Inc.20$150,769
AbbVie(2 entities)110$144,720
Novartis59$127,238
Genentech, Inc.26$119,092
Incyte Corporation137$88,384
Sanofi92$85,220
Chiesi USA, Inc.24$78,122
Boehringer Ingelheim Pharma GmbH & Co.kg3$57,961
Amgen64$56,501
Mylan Specialty L.p.13$37,746
Regeneron14$19,567
Boehringer Ingelheim International GmbH130$16,730
E.r. Squibb & Sons, L.L.C.4$14,760
Pfizer52$14,222
Astrazeneca AB2$3,763
Sunovion Pharmaceuticals Inc.12$3,433
Genentech USA, Inc.18$1,835
Regeneron Healthcare Solutions, Inc.55$1,501
Grifols USA, LLC92$1,481
Takeda Pharmaceuticals U.S.A., Inc.43$970
Verathon Inc.1$500
Baxter Healthcare23$460
Lilly USA, LLC25$456
Hill-rom Services, Inc1$450
Johnson & Johnson25$442
Octapharma USA, Inc.13$366
Inari Medical, Inc.15$344
Merck16$241
Novo Nordisk12$219
Advanced Respiratory, Inc9$215
ANI Pharmaceuticals, Inc.8$202
Otsuka America Pharmaceutical, Inc.8$157
Astellas Pharma US Inc6$132
Exact Sciences6$128
Shionogi Inc8$127
Amarin Pharma, Inc.7$107
Esperion Therapeutics, Inc.6$101
Vifor Pharma, Inc.4$91
Veran Medical Technologies, Inc.2$89
Philips North America LLC5$76
Nabriva Therapeutics, PLC4$73
Stryker2$68
Sanofi-aventis U.S. LLC2$66
Harmony Biosciences LLC4$61
Gilead2$59
Teva Pharmaceuticals USA, Inc.4$57
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$53
Actelion Pharmaceuticals US, Inc.5$53
Optinose US, Inc.2$50
Circassia Inc.3$44
Verona Pharma, Inc.2$42
Alnylam Pharmaceuticals Inc.2$41
Radius Health, Inc.2$41

How this compares

$5,005,752 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024
$2,798,870
Medicare patients
510
Services billed
158,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Newport Beach

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →